Clinical Trials
5 trialsNCT05144529 2026-05-05
TOP2101
Duke University
Phase 2 Terminated
NCT06284564 2026-04-21
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04862260 2026-03-19
Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
CHU de Quebec-Universite Laval
Phase EARLY_PHASE1 Active not recruiting
NCT04937413 2024-06-25
The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation
Duke University
Phase EARLY_PHASE1 Completed
NCT05976893 2023-08-04
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Xinjiang Medical University
Phase 4 Unknown